Altimmune to Present at Upcoming Scientific Conferences
April 29 2021 - 7:00AM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that members of the Company’s management
team will be presenting at two scientific conferences in May 2021.
Scot Roberts, Ph.D., Chief Scientific Officer at
Altimmune and Dr. Sarah K. Browne, Senior Director, Vaccine
Development at Altimmune will give an oral presentation
highlighting the Company’s AdCOVID™ intranasal COVID-19 vaccine
candidate at the World Vaccine Congress, taking place May 4-7,
2021.
Dr. Scott Harris, Chief Medical Officer at
Altimmune will give an oral presentation at the Chronic Hepatitis B
Drug Development Virtual Summit, taking place May 5-6, 2021, during
which he will provide an overview of HepTcell™, a novel
peptide-based immunotherapeutic being developed by Altimmune for
the treatment of chronic hepatitis B (CHB).
Details on the World Vaccine Congress
presentation are as follows:
Title: |
AdCOVID – A Single-Dose Intranasal Vaccine for COVID-19 |
|
|
Presenters: |
Scot Roberts, Ph.D., Chief
Scientific Officer at AltimmuneDr. Sarah K. Browne, Senior
Director, Vaccine Development at Altimmune |
|
|
Date: |
May 4, 2021 (virtual pre-record
available) |
Details on the Chronic Hepatitis B Drug
Development Virtual Summit presentation are as follows:
Title: |
How We Can Achieve Success with Immunotherapeutics in the Treatment
of Chronic Hepatitis B |
|
|
Presenter: |
Scott Harris M.D., Chief Medical
Officer at Altimmune. Inc. |
|
|
Date/Time: |
May 5, 2021 at 1:30 pm ET |
A copy of the presentation materials will be
accessible on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical stage biopharmaceutical
company focused on developing intranasal vaccines, immune
modulating therapies and treatments for liver disease. Our diverse
pipeline includes proprietary intranasal vaccines for COVID-19
(AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an
intranasal immune modulating therapeutic for COVID-19 (T-COVID™);
and next generation peptide therapeutics for NASH (ALT-801) and
chronic hepatitis B (HepTcell™). For more information on Altimmune,
please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Altimmune Investor & Media Contacts:
Will
Brown |
Stacey
Jurchison |
Chief Financial Officer |
Sr. Dir, Investor Relations |
Phone: 240-654-1450 |
Phone : 410-474-8200 |
wbrown@altimmune.com |
sjurchison@altimmune.com |
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2023 to Apr 2024